左心房付属器（LAA）閉鎖デバイス市場：製品別（心内膜LAAデバイス、心外膜LAAデバイス）、エンドユース別（病院、外来手術センター、その他）：世界の機会分析および産業予測、2021-2031年

世界の左心房付属器（LAA）閉鎖デバイス市場は、2021年の12億7690万米ドルから2022年から2031年にかけてCAGR20.97％で成長し、2031年までに82億1810万米ドルを獲得すると想定されます。

世界の左心房付属器（LAA）閉鎖デバイスは心臓に埋め込まれ、非弁膜症性心房細動患者の左心房付属器（LAA）からの血栓塞栓症リスクを低減することを目的としています。本装置は、LAAを機械的に閉塞し、LAA血栓が体内の循環血液に流入することを防ぎます。LAA閉塞は心房細動に伴う脳卒中リスクを低減します。しかし、心房細動そのものを治療するわけではありません。左心房付属器閉鎖術は、心臓手術が必要で、かつ心房細動がある人に有効です。また、心房細動のある人にもこの手術は有効です。

心房細動の有病率の上昇は、左心房付属器閉鎖デバイスの必要性を増大させると予想されます。心房細動は、先天性心疾患を患う患者に最も多く見られる心房性不整脈の1つです。また、高齢者は不整脈、虚血性脳卒中、心房細動の影響を受けやすいため、高齢化により心房細動の発生が増加すると考えられています。このような要因が、左心房付属器（LAA）閉鎖デバイスの市場価値を押し上げると予想されます。

しかし、代替品の利用可能性や左心房付属器閉鎖デバイスの高コストが、市場拡大にマイナスの影響を与える可能性があります。経口抗凝固療法は、左心房付属器閉鎖デバイスの従来の代替品であり、非弁膜症性心房細動の医師によって広く好まれています。リバーロキサバン、ダビガトラン、アピキサバン、エドキサバンなどの非ビタミン系経口抗凝固薬（NOACs）の開発により、脳卒中管理における血栓塞栓事象の感受性が高い患者の経口抗凝固薬使用が促進されています。このような要因は、左心房付属器（LAA）閉鎖デバイス市場の成長を制限すると予想されます。

COVID-19のパンデミックは、世界中の様々なビジネスが停止していたように、深刻な経済的損失につながるいくつかの不確実性をもたらしました。米国や中国などの主要な左心房付属器閉鎖デバイス生産国には輸出入規制が敷かれ、市場に大きな打撃を与えました。COVID-19は、血栓炎症カスケードを促進し、凝固を激化させ、心房細動患者の心筋梗塞のリスクを高める可能性があります。パンデミック時のICUベッドに関する制限は、左心房閉鎖術を含む心臓手術の実施に大きな制約となり、左心房閉鎖器具の使用を減少させることになります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

• 市場の定義と範囲
• 主な調査結果
  • 主な投資ポケット
• ポーターのファイブフォース分析
• 主要企業のポジショニング
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• COVID-19 影響分析
• 規制ガイドライン
• バリューチェーン分析
• 市場シェア分析
• 主要規制の分析
• 特許情勢

第4章 左心房付属器（LAA）閉鎖デバイス市場：製品別

• 概要
  • 市場規模および予測
• 心内膜型LAAデバイス
  • 主な市場動向、成長要因、機会
  • 市場規模・予測：地域別
  • 市場分析：国別
• 心外膜LAAデバイス
  • 主な市場動向、成長要因、機会
  • 市場規模・予測：地域別
  • 市場分析：国別

第5章 左心房付属器（LAA）閉鎖デバイス市場：エンドユーザー別

• 概要
  • 市場規模および予測
• 病院
  • 主な市場動向、成長要因、機会
  • 市場規模・予測：地域別
  • 市場分析：国別
• 外来手術センター
  • 主な市場動向、成長要因、機会
  • 市場規模・予測：地域別
  • 市場分析：国別
• その他
  • 主な市場動向、成長要因、機会
  • 市場規模・予測：地域別
  • 市場分析：国別

第6章 左心房付属器（LAA）閉鎖デバイス（LAA）市場：地域別

• 概要
  • 市場規模・予測
• 北米
  • 主な動向と機会
  • 北米の市場規模・予測：製品別
  • 北米市場規模・予測：エンドユーザー別
  • 北米市場規模・予測：国別
    • 米国
    • カナダ
    • メキシコ
• 欧州
  • 主な動向と機会
  • 欧州市場規模・予測：製品別
  • 欧州市場規模・予測：エンドユーザー別
  • 欧州市場規模・予測：国別
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州地域
• アジア太平洋地域
  • 主な動向と機会
  • アジア太平洋地域の市場規模・予測：製品別
  • アジア太平洋地域の市場規模・予測：エンドユーザー別
  • アジア太平洋地域の市場規模・予測：国別
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
• LAMEA
  • 主な動向と機会
  • LAMEAの市場規模・予測：製品別
  • LAMEAの市場規模・予測：エンドユーザー別
  • LAMEAの市場規模・予測：国別
    • ブラジル
    • サウジアラビア
    • UAE
    • 南アフリカ
    • LAMEAの残りの地域

第7章 企業情勢

• イントロダクション
• 主要成功戦略
• 主要10社の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主な発展

第8章 企業プロファイル

• sentreheart, inc.
• Boston Scientific Corporation
• AtriCure, Inc.
• Abbott Laboratories
• Occlutech
• lifetech scientific corporation
• Cardia, Inc.
• Aegis Medical Group.
• Biosense Webster, Inc.
• Johnson & Johnson Services, Inc.

LIST OF TABLES

• TABLE 1. GLOBAL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 2. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR ENDOCARDIAL LAA DEVICES, BY REGION, 2021-2031 ($MILLION)
• TABLE 3. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR ENDOCARDIAL LAA DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 4. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR EPICARDIAL LAA DEVICES, BY REGION, 2021-2031 ($MILLION)
• TABLE 5. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR EPICARDIAL LAA DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 6. GLOBAL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 7. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
• TABLE 8. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 9. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2031 ($MILLION)
• TABLE 10. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 11. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
• TABLE 12. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 13. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY REGION, 2021-2031 ($MILLION)
• TABLE 14. NORTH AMERICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 15. NORTH AMERICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 16. NORTH AMERICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 17. U.S. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 18. U.S. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 19. CANADA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 20. CANADA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 21. MEXICO LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 22. MEXICO LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 23. EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 24. EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 25. EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 26. GERMANY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 27. GERMANY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 28. UNITED KINGDOM LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 29. UNITED KINGDOM LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 30. FRANCE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 31. FRANCE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 32. SPAIN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 33. SPAIN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 34. ITALY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 35. ITALY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 36. REST OF EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 37. REST OF EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 38. ASIA-PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 39. ASIA-PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 40. ASIA-PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 41. CHINA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 42. CHINA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 43. JAPAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 44. JAPAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 45. INDIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 46. INDIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 47. SOUTH KOREA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 48. SOUTH KOREA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 49. AUSTRALIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 50. AUSTRALIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 51. REST OF ASIA PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 52. REST OF ASIA PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 53. LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 54. LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 55. LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
• TABLE 56. BRAZIL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 57. BRAZIL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 58. SAUDI ARABIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 59. SAUDI ARABIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 60. UAE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 61. UAE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 62. SOUTH AFRICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 63. SOUTH AFRICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 64. REST OF LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
• TABLE 65. REST OF LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
• TABLE 66.SENTREHEART, INC.: COMPANY SNAPSHOT
• TABLE 67.SENTREHEART, INC.: OPERATING SEGMENTS
• TABLE 68.SENTREHEART, INC.: PRODUCT PORTFOLIO
• TABLE 69.SENTREHEART, INC.: NET SALES,
• TABLE 70.SENTREHEART, INC.: KEY STRATERGIES
• TABLE 71.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
• TABLE 72.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
• TABLE 73.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
• TABLE 74.BOSTON SCIENTIFIC CORPORATION: NET SALES,
• TABLE 75.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
• TABLE 76.ATRICURE, INC.: COMPANY SNAPSHOT
• TABLE 77.ATRICURE, INC.: OPERATING SEGMENTS
• TABLE 78.ATRICURE, INC.: PRODUCT PORTFOLIO
• TABLE 79.ATRICURE, INC.: NET SALES,
• TABLE 80.ATRICURE, INC.: KEY STRATERGIES
• TABLE 81.ABBOTT LABORATORIES: COMPANY SNAPSHOT
• TABLE 82.ABBOTT LABORATORIES: OPERATING SEGMENTS
• TABLE 83.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
• TABLE 84.ABBOTT LABORATORIES: NET SALES,
• TABLE 85.ABBOTT LABORATORIES: KEY STRATERGIES
• TABLE 86.OCCLUTECH: COMPANY SNAPSHOT
• TABLE 87.OCCLUTECH: OPERATING SEGMENTS
• TABLE 88.OCCLUTECH: PRODUCT PORTFOLIO
• TABLE 89.OCCLUTECH: NET SALES,
• TABLE 90.OCCLUTECH: KEY STRATERGIES
• TABLE 91.LIFETECH SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
• TABLE 92.LIFETECH SCIENTIFIC CORPORATION: OPERATING SEGMENTS
• TABLE 93.LIFETECH SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
• TABLE 94.LIFETECH SCIENTIFIC CORPORATION: NET SALES,
• TABLE 95.LIFETECH SCIENTIFIC CORPORATION: KEY STRATERGIES
• TABLE 96.CARDIA, INC.: COMPANY SNAPSHOT
• TABLE 97.CARDIA, INC.: OPERATING SEGMENTS
• TABLE 98.CARDIA, INC.: PRODUCT PORTFOLIO
• TABLE 99.CARDIA, INC.: NET SALES,
• TABLE 100.CARDIA, INC.: KEY STRATERGIES
• TABLE 101.AEGIS MEDICAL GROUP.: COMPANY SNAPSHOT
• TABLE 102.AEGIS MEDICAL GROUP.: OPERATING SEGMENTS
• TABLE 103.AEGIS MEDICAL GROUP.: PRODUCT PORTFOLIO
• TABLE 104.AEGIS MEDICAL GROUP.: NET SALES,
• TABLE 105.AEGIS MEDICAL GROUP.: KEY STRATERGIES
• TABLE 106.BIOSENSE WEBSTER, INC.: COMPANY SNAPSHOT
• TABLE 107.BIOSENSE WEBSTER, INC.: OPERATING SEGMENTS
• TABLE 108.BIOSENSE WEBSTER, INC.: PRODUCT PORTFOLIO
• TABLE 109.BIOSENSE WEBSTER, INC.: NET SALES,
• TABLE 110.BIOSENSE WEBSTER, INC.: KEY STRATERGIES
• TABLE 111.JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
• TABLE 112.JOHNSON & JOHNSON SERVICES, INC.: OPERATING SEGMENTS
• TABLE 113.JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
• TABLE 114.JOHNSON & JOHNSON SERVICES, INC.: NET SALES,
• TABLE 115.JOHNSON & JOHNSON SERVICES, INC.: KEY STRATERGIES

LIST OF FIGURES

• FIGURE 1.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET SEGMENTATION
• FIGURE 2.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031
• FIGURE 3.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031
• FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
• FIGURE 5.PORTER FIVE-1
• FIGURE 6.PORTER FIVE-2
• FIGURE 7.PORTER FIVE-3
• FIGURE 8.PORTER FIVE-4
• FIGURE 9.PORTER FIVE-5
• FIGURE 10.TOP PLAYER POSITIONING
• FIGURE 11.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
• FIGURE 12.REGULATORY GUIDELINES
• FIGURE 13.VALUE CHAIN ANALYSIS
• FIGURE 14.MARKET SHARE ANALYSIS
• FIGURE 15.KEY REGULATION ANALYSIS
• FIGURE 16.PATENT ANALYSIS BY COMPANY
• FIGURE 17.PATENT ANALYSIS BY COUNTRY
• FIGURE 18.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,BY PRODUCT,2021(%)
• FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENDOCARDIAL LAA DEVICES LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
• FIGURE 20.COMPARATIVE SHARE ANALYSIS OF EPICARDIAL LAA DEVICES LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
• FIGURE 21.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,BY END USE,2021(%)
• FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
• FIGURE 23.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGERY CENTERS LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
• FIGURE 24.COMPARATIVE SHARE ANALYSIS OF OTHERS LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
• FIGURE 25.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET BY REGION,2021
• FIGURE 26.U.S. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 27.CANADA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 28.MEXICO LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 29.GERMANY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 30.UNITED KINGDOM LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 31.FRANCE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 32.SPAIN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 33.ITALY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 34.REST OF EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 35.CHINA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 36.JAPAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 37.INDIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 38.SOUTH KOREA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 39.AUSTRALIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 40.REST OF ASIA PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 41.BRAZIL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 42.SAUDI ARABIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 43.UAE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 44.SOUTH AFRICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 45.REST OF LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
• FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
• FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
• FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
• FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 50.COMPETITIVE DASHBOARD
• FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
• FIGURE 52.SENTREHEART, INC..: NET SALES ,($MILLION)
• FIGURE 53.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
• FIGURE 54.ATRICURE, INC..: NET SALES ,($MILLION)
• FIGURE 55.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
• FIGURE 56.OCCLUTECH.: NET SALES ,($MILLION)
• FIGURE 57.LIFETECH SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
• FIGURE 58.CARDIA, INC..: NET SALES ,($MILLION)
• FIGURE 59.AEGIS MEDICAL GROUP..: NET SALES ,($MILLION)
• FIGURE 60.BIOSENSE WEBSTER, INC..: NET SALES ,($MILLION)
• FIGURE 61.JOHNSON & JOHNSON SERVICES, INC..: NET SALES ,($MILLION)

The global left atrial appendage (LAA) closure device market is envisioned to garner $8,218.10 million by 2031, growing from $1,276.90 million in 2021 at a CAGR of 20.97% from 2022 to 2031.

The global Left Atrial Appendage (LAA) Closure device is implanted in the heart and is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The device mechanically occludes the LAA to prevent LAA thrombus from entering the circulation of the blood in the body. LAA closure reduces the stroke risk associated with atrial fibrillation. But, it doesn't treat the AFib itself. Left atrial appendage closure can benefit people who need heart surgery and also have atrial fibrillation. The procedure is also helpful for those who have atrial fibrillation.

The rising prevalence of atrial fibrillation is anticipated to augment the need for left atrial appendage closure devices. Atrial fibrillation was one the most prevalent atrial arrhythmia in patients suffering from congenital heart disease. Additionally, the aging population will increase atrial fibrillation disease incidences, as elderly adults are more susceptible to arrhythmia, ischemic stroke disease, and atrial fibrillation. Such factors are anticipated to drive the Left Atrial Appendage (LAA) Closure device market value.

However, the availability of alternatives and the high cost of left atrial appendage atrial closure devices may negatively impact the market expansion. Oral anticoagulation is the conventional alternative to left atrial appendage closure devices and is extensively preferred by doctors with non-valvular atrial fibrillation. The development of non-vitamin oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban have facilitated the use of oral anti-coagulants among patients that are susceptible to thromboembolic events in stroke management. Such factors are anticipated to restrict the Left Atrial Appendage (LAA) Closure device market growth.

The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. There were import-export restrictions laid down on major Left Atrial Appendage (LAA) Closure device-producing countries such as the United States and China, which imposed significant challenges on the market. COVID-19 virus enhances the thrombo-inflammatory cascade, which intensifies coagulation and may increase the risk of cardiac embolism in patients with AF. The limitations regarding the ICU beds during the pandemic represent a major restriction in performing heart surgeries including left atrial appendage closure procedures, thereby reducing the usage of left atrial appendage closure devices.

The key players profiled in the Left Atrial Appendage (LAA) Closure Device market report include Boston Scientific Corporation, Abbott, Lifetech Scientific, ATRICURE, INC., SentreHEART, Inc., Medical Device Business Services, Inc., Occlutech, Cardia, Inc., Johnson & Johnson Private Limited, and Lepu Medical Technology Co., Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the left atrial appendage (LAA) closure device market analysis from 2021 to 2031 to identify the prevailing left atrial appendage (LAA) closure device market opportunities.
• Market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
• An in-depth analysis of the left atrial appendage (LAA) closure device market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global left atrial appendage (LAA) closure device market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

• Endocardial LAA Devices
• Epicardial LAA Devices

By End Use

• Hospitals
• Ambulatory Surgery Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest Of Asia Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of LAMEA
• Key Market Players
  • sentreheart, inc.
  • Boston Scientific Corporation
  • AtriCure, Inc.
  • Abbott Laboratories
  • Occlutech
  • lifetech scientific corporation
  • Cardia, Inc.
  • Aegis Medical Group.
  • Biosense Webster, Inc.
  • Johnson & Johnson Services, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Regulatory Guidelines
• 3.8.Value Chain Analysis
• 3.9.Market Share Analysis
• 3.10.Key Regulation Analysis
• 3.11.Patent Landscape

CHAPTER 4: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Endocardial LAA Devices
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Epicardial LAA Devices
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country

CHAPTER 5: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Hospitals
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Ambulatory Surgery Centers
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Others
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country

CHAPTER 6: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY REGION

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 North America
  • 6.2.1 Key trends and opportunities
  • 6.2.2 North America Market size and forecast, by Product
  • 6.2.3 North America Market size and forecast, by End Use
  • 6.2.4 North America Market size and forecast, by country
    • 6.2.4.1 U.S.
    • 6.2.4.1.1 Market size and forecast, by Product
    • 6.2.4.1.2 Market size and forecast, by End Use
    • 6.2.4.2 Canada
    • 6.2.4.2.1 Market size and forecast, by Product
    • 6.2.4.2.2 Market size and forecast, by End Use
    • 6.2.4.3 Mexico
    • 6.2.4.3.1 Market size and forecast, by Product
    • 6.2.4.3.2 Market size and forecast, by End Use
• 6.3 Europe
  • 6.3.1 Key trends and opportunities
  • 6.3.2 Europe Market size and forecast, by Product
  • 6.3.3 Europe Market size and forecast, by End Use
  • 6.3.4 Europe Market size and forecast, by country
    • 6.3.4.1 Germany
    • 6.3.4.1.1 Market size and forecast, by Product
    • 6.3.4.1.2 Market size and forecast, by End Use
    • 6.3.4.2 United Kingdom
    • 6.3.4.2.1 Market size and forecast, by Product
    • 6.3.4.2.2 Market size and forecast, by End Use
    • 6.3.4.3 France
    • 6.3.4.3.1 Market size and forecast, by Product
    • 6.3.4.3.2 Market size and forecast, by End Use
    • 6.3.4.4 Spain
    • 6.3.4.4.1 Market size and forecast, by Product
    • 6.3.4.4.2 Market size and forecast, by End Use
    • 6.3.4.5 Italy
    • 6.3.4.5.1 Market size and forecast, by Product
    • 6.3.4.5.2 Market size and forecast, by End Use
    • 6.3.4.6 Rest of Europe
    • 6.3.4.6.1 Market size and forecast, by Product
    • 6.3.4.6.2 Market size and forecast, by End Use
• 6.4 Asia-Pacific
  • 6.4.1 Key trends and opportunities
  • 6.4.2 Asia-Pacific Market size and forecast, by Product
  • 6.4.3 Asia-Pacific Market size and forecast, by End Use
  • 6.4.4 Asia-Pacific Market size and forecast, by country
    • 6.4.4.1 China
    • 6.4.4.1.1 Market size and forecast, by Product
    • 6.4.4.1.2 Market size and forecast, by End Use
    • 6.4.4.2 Japan
    • 6.4.4.2.1 Market size and forecast, by Product
    • 6.4.4.2.2 Market size and forecast, by End Use
    • 6.4.4.3 India
    • 6.4.4.3.1 Market size and forecast, by Product
    • 6.4.4.3.2 Market size and forecast, by End Use
    • 6.4.4.4 South Korea
    • 6.4.4.4.1 Market size and forecast, by Product
    • 6.4.4.4.2 Market size and forecast, by End Use
    • 6.4.4.5 Australia
    • 6.4.4.5.1 Market size and forecast, by Product
    • 6.4.4.5.2 Market size and forecast, by End Use
    • 6.4.4.6 Rest Of Asia Pacific
    • 6.4.4.6.1 Market size and forecast, by Product
    • 6.4.4.6.2 Market size and forecast, by End Use
• 6.5 LAMEA
  • 6.5.1 Key trends and opportunities
  • 6.5.2 LAMEA Market size and forecast, by Product
  • 6.5.3 LAMEA Market size and forecast, by End Use
  • 6.5.4 LAMEA Market size and forecast, by country
    • 6.5.4.1 Brazil
    • 6.5.4.1.1 Market size and forecast, by Product
    • 6.5.4.1.2 Market size and forecast, by End Use
    • 6.5.4.2 Saudi Arabia
    • 6.5.4.2.1 Market size and forecast, by Product
    • 6.5.4.2.2 Market size and forecast, by End Use
    • 6.5.4.3 UAE
    • 6.5.4.3.1 Market size and forecast, by Product
    • 6.5.4.3.2 Market size and forecast, by End Use
    • 6.5.4.4 South Africa
    • 6.5.4.4.1 Market size and forecast, by Product
    • 6.5.4.4.2 Market size and forecast, by End Use
    • 6.5.4.5 Rest of LAMEA
    • 6.5.4.5.1 Market size and forecast, by Product
    • 6.5.4.5.2 Market size and forecast, by End Use

CHAPTER 7: COMPANY LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product Mapping of Top 10 Player
• 7.4. Competitive Dashboard
• 7.5. Competitive Heatmap
• 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

• 8.1 sentreheart, inc.
  • 8.1.1 Company overview
  • 8.1.2 Company snapshot
  • 8.1.3 Operating business segments
  • 8.1.4 Product portfolio
  • 8.1.5 Business performance
  • 8.1.6 Key strategic moves and developments
• 8.2 Boston Scientific Corporation
  • 8.2.1 Company overview
  • 8.2.2 Company snapshot
  • 8.2.3 Operating business segments
  • 8.2.4 Product portfolio
  • 8.2.5 Business performance
  • 8.2.6 Key strategic moves and developments
• 8.3 AtriCure, Inc.
  • 8.3.1 Company overview
  • 8.3.2 Company snapshot
  • 8.3.3 Operating business segments
  • 8.3.4 Product portfolio
  • 8.3.5 Business performance
  • 8.3.6 Key strategic moves and developments
• 8.4 Abbott Laboratories
  • 8.4.1 Company overview
  • 8.4.2 Company snapshot
  • 8.4.3 Operating business segments
  • 8.4.4 Product portfolio
  • 8.4.5 Business performance
  • 8.4.6 Key strategic moves and developments
• 8.5 Occlutech
  • 8.5.1 Company overview
  • 8.5.2 Company snapshot
  • 8.5.3 Operating business segments
  • 8.5.4 Product portfolio
  • 8.5.5 Business performance
  • 8.5.6 Key strategic moves and developments
• 8.6 lifetech scientific corporation
  • 8.6.1 Company overview
  • 8.6.2 Company snapshot
  • 8.6.3 Operating business segments
  • 8.6.4 Product portfolio
  • 8.6.5 Business performance
  • 8.6.6 Key strategic moves and developments
• 8.7 Cardia, Inc.
  • 8.7.1 Company overview
  • 8.7.2 Company snapshot
  • 8.7.3 Operating business segments
  • 8.7.4 Product portfolio
  • 8.7.5 Business performance
  • 8.7.6 Key strategic moves and developments
• 8.8 Aegis Medical Group.
  • 8.8.1 Company overview
  • 8.8.2 Company snapshot
  • 8.8.3 Operating business segments
  • 8.8.4 Product portfolio
  • 8.8.5 Business performance
  • 8.8.6 Key strategic moves and developments
• 8.9 Biosense Webster, Inc.
  • 8.9.1 Company overview
  • 8.9.2 Company snapshot
  • 8.9.3 Operating business segments
  • 8.9.4 Product portfolio
  • 8.9.5 Business performance
  • 8.9.6 Key strategic moves and developments
• 8.10 Johnson & Johnson Services, Inc.
  • 8.10.1 Company overview
  • 8.10.2 Company snapshot
  • 8.10.3 Operating business segments
  • 8.10.4 Product portfolio
  • 8.10.5 Business performance
  • 8.10.6 Key strategic moves and developments